Honor Hightshue
Nurse Practitioner · Chattanooga, TNNPI 1578765772
Payments from drug & device makers
Across 560 payments — averaging $80.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$14K
- Dermavant Sciences, Inc.$7K
- Blueprint Medicines Corporation$7K
- Novartis$4K
- AstraZeneca$3K
- Pharming Healthcare, Inc.$2K
- plus $8K from 31 others
What the payments were for
- Consulting fees$8,96420%
- Speaking & faculty fees$16,49137%
- Travel & lodging$3,1237%
- Food & beverage$16,13336%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 68 | $13,943 |
| Dermavant Sciences, Inc. | 17 | $7,110 |
| Blueprint Medicines Corporation | 40 | $6,980 |
| Novartis | 22 | $3,645 |
| AstraZeneca | 69 | $3,420 |
| Pharming Healthcare, Inc. | 13 | $1,573 |
| GSK | 63 | $973 |
| Regeneron Healthcare Solutions, Inc. | 33 | $935 |
| Sanofi | 29 | $850 |
| Pfizer | 34 | $816 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $752 |
| Grifols USA, LLC | 14 | $433 |
| AbbVie | 14 | $429 |
| Amgen(2 entities) | 19 | $393 |
| Biocryst US Sales Co., LLC | 7 | $386 |
| Optinose US, Inc. | 16 | $290 |
| Incyte Corporation | 4 | $249 |
| Organon | 3 | $215 |
| Genentech USA, Inc. | 11 | $203 |
| Ionis Pharmaceuticals, Inc. | 6 | $201 |
| Octapharma USA, Inc. | 3 | $181 |
| Covis Pharma GmbH | 9 | $177 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $151 |
| Teva Pharmaceuticals USA, Inc. | 3 | $137 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Greer Laboratories, Inc. | 1 | $66 |
| X4 Pharmaceuticals, Inc. | 2 | $62 |
| ADMA Biomanufacturing LLC | 2 | $41 |
| Kaleo, Inc. | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Merck | 1 | $22 |
| Abbott | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Alk-abello, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,887 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $66,473 |
| Dupixent PenDupilumab | 15 | $65,787 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,288 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $14,350 |
| Epinephrine | 38 | $7,172 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $6,153 |
| DuleraMometasone/Formoterol | 15 | $5,342 |
| Azelastine Hcl | 105 | $4,919 |
| Ipratropium Bromide | 83 | $4,329 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $4,070 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,055 |
| Montelukast Sodium | 283 | $3,727 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 159 | $3,715 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,337 |
| Olopatadine Hcl | 26 | $3,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $973 | $81,762116 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,420 | $18,40526 claims |
| Hikma Pharmaceuticals USAEpinephrine | $30 | $7,17238 claims |
| MerckDulera | $22 | $5,34215 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $137 | $4,07014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.